MTOR and urinary bladder carcinoma: Hence, combining the mTOR inhibitor everolimus with a naturally derived epigenetic drug such as SFN may provide an innovative strategy in treating bladder cancer by acetylating histones H3 and H4 and concomitantly elevating the tumor suppressor p19.